FDA Okays LLY's Omvoh for Second Inflammatory Bowel Disease Condition

Eli Lilly and Company (LLY) announced that the FDA has granted approval to its drug, Omvoh (mirikizumab), for its second inflammatory bowel disease (IBD) condition, Crohn's disease (“CD”), in the United States. Omvoh was approved for its first IBD indication, moderately to severely active ulcerative colitis (“UC”), in 2023. The drug is currently approved for UC in 44 countries.The approval of Omvoh for moderately to severely active CD in adults was based on data from the VIVID 1 study. The study met both it ...